Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its business prospects and financial reporting [1][2]. Allegations - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2]. - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2]. - The business model of Tempus-acquired Ambry is criticized for aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2]. - These issues indicate weaknesses in Tempus' core operations and revenue prospects [2]. Financial Reporting Scrutiny - A report by Spruce Point Capital Management highlighted several red flags regarding Tempus' management and operations, including a history of executives cashing out before public shareholders incur losses [3]. - The report claims that Tempus' actual AI capabilities are overstated and that there are signs of aggressive accounting and financial reporting [3]. - Concerns were also raised about the AstraZeneca and Pathos AI deal, which merits further scrutiny [3]. - Recent financial guidance from the company reveals weaknesses in its core operations [3]. Stock Price Impact - Following the news of the allegations and the report, Tempus' stock price fell by $12.67 per share, or 19.23%, from $65.87 on May 27, 2025, to $53.20 on May 28, 2025 [4].

Key Takeaways TEM receives FDA 510(k) clearance for its ECG-Low EF AI software for detecting low ejection fraction. TEM's AI tool analyzes 12-lead ECGs from patients aged 40+ at risk of heart failure in clinical settings. TEM's ECG-Low EF is its second FDA-cleared AI ECG device amid at rapid market growth in the cardiology space.The integration of artificial intelligence (AI) in the cardiovascular space, particularly in electrocardiography (ECG), is reshaping clinical workflows, enabling earlier disease d ...

Core Insights - Tempus AI (TEM) experienced a 7.3% increase in stock price after receiving FDA 510(k) clearance for its ECG-Low EF software, marking its second AI tool approved in cardiology [1] - The company reported a 75% increase in revenues and nearly doubled gross profit in Q1 2025, alongside a $200 million foundation model deal with AstraZeneca and Pathos [1][8] Stock Performance - Over the past three months, TEM stock surged by 48.3%, significantly outperforming the Medical Info Systems industry (11.9%) and the Medical sector (1%) [2] - The S&P 500 index rose by 18.7% during the same period, indicating strong relative performance for Tempus AI [2] Strategic Developments - The FDA clearance for the ECG-Low EF software enhances Tempus AI's clinical diagnostics portfolio, enabling earlier detection of heart failure risks through standard ECGs [5] - A $200 million partnership with AstraZeneca and Pathos aims to develop a large oncology foundation model, increasing Tempus AI's total contract value to over $1 billion [6][8] Revenue Growth - The hereditary testing segment, bolstered by the integration of Ambry Genetics, generated $63.5 million in revenue, reflecting a 23% increase in testing volumes [9] - This growth indicates a successful expansion into inherited disease risk assessment, tapping into a larger market of at-risk individuals [9] Valuation Metrics - The average price target for TEM suggests a potential increase of 19.3% from the last closing price of $66.70 [10] - Currently, TEM is trading at a forward 12-month price-to-sales (P/S) ratio of 7.34, higher than the industry average of 5.56 and peers like iRhythm (5.78) and SOPHiA GENETICS (2.80) [13] Long-term Outlook - Despite impressive momentum and growth, the stock's high valuation relative to peers suggests a cautious near-term approach [14] - Long-term fundamentals remain strong, with ongoing innovation and execution in diagnostics, data licensing, and AI platform development [16]

Core Viewpoint - Class actions have been initiated against Vestis Corporation, Reckitt Benckiser Group, and Tempus AI, highlighting significant legal challenges and potential financial implications for these companies [1][4][6]. Group 1: Vestis Corporation (NYSE: VSTS) - The class period for Vestis is from May 2, 2024, to May 6, 2025, with a lead plaintiff deadline of August 8, 2025 [2]. - The complaint alleges that Vestis made misleading statements about its business growth capabilities, particularly regarding customer retention and revenue generation [2]. - Following a disappointing financial report on May 7, 2025, Vestis' stock price plummeted from $8.71 to $5.44, a decline of approximately 37.54% in one day [3]. Group 2: Reckitt Benckiser Group plc (OTC: RBGLY) - The class period for Reckitt is from January 13, 2021, to July 28, 2024, with a lead plaintiff deadline of August 4, 2025 [4]. - Over 500 lawsuits have been filed against Reckitt, alleging failure to warn about the risks associated with its cow's milk-based formula, Enfamil, which is linked to a serious intestinal disease in premature infants [4][5]. - The allegations include misleading statements regarding the safety of Reckitt's products and the potential impact on sales and legal exposure [5]. Group 3: Tempus AI, Inc. (NASDAQ: TEM) - The class period for Tempus is from August 6, 2024, to May 27, 2025, with a lead plaintiff deadline of August 11, 2025 [6]. - The complaint claims that Tempus failed to disclose significant issues, including inflated contract values and questionable business practices that could jeopardize its financial stability [6]. - Following a critical report from Spruce Point Capital Management on May 28, 2025, Tempus' stock price fell from $65.87 to $53.20, a decrease of 19.23% [7][8].

Core Insights - Tempus AI (TEM) has raised its full-year 2025 revenue guidance to $1.25 billion, reflecting an 80% annual growth, and expects adjusted EBITDA of $5 million, an improvement of approximately $110 million over 2024 [2][9]. Financial Performance - In Q1, Tempus reported total sales of $255.7 million, a year-over-year increase of 75.4%, with gross profit rising 99.8% to $155.2 million [3][9]. - The adjusted EBITDA loss narrowed to $16.2 million from $43.9 million a year ago, indicating improved operational efficiency [3]. Strategic Collaborations - Tempus entered a three-year, $200 million agreement with AstraZeneca and Pathos to develop a multimodal foundation model in oncology, utilizing over 300 petabytes of healthcare data [4]. - This collaboration has increased the total remaining contract value to over $1 billion as of the end of April [4]. Growth in Hereditary Testing - Revenues from hereditary testing reached $63.5 million, driven by a 23% volume growth, surpassing initial guidance [5]. - The acquisition of Ambry Genetics is expected to enhance long-term growth potential in this segment, extending beyond oncology to other genetic predispositions [5]. Competitor Outlook - Exact Sciences (EXAS) anticipates 2025 revenues between $3.070 billion and $3.120 billion, with an adjusted EBITDA forecast of $425-$455 million, driven by the successful launch of Cologuard Plus [6]. - Exelixis (EXEL) raised its 2025 revenue guidance to $2.25-$2.35 billion following strong demand for CABOMETYX and recent FDA approvals [7]. Stock Performance - Tempus AI shares have increased by 58.6% over the past year, outperforming the industry growth of 16.8% and the S&P 500's 11% [10]. Valuation Metrics - Tempus currently trades at a forward Price-to-Sales (P/S) ratio of 7.09, compared to the industry average of 5.82 [11].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific allegations of misleading statements and undisclosed risks during designated class periods [1][2][3][4][5]. Group 1: Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) - Class period is from February 27, 2025, to May 26, 2025, with a lead plaintiff deadline of August 11, 2025 [2]. - Allegations include that Rocket was aware of serious adverse events (SAEs), including participant deaths, and failed to disclose this risk [2]. - The company amended trial protocols without informing shareholders, leading to misleading positive statements about its business and prospects [2]. Group 2: 3D Systems Corporation (NYSE: DDD) - Class period is from August 13, 2024, to May 12, 2025, with a lead plaintiff deadline of August 12, 2025 [3]. - Allegations state that 3D Systems understated the impact of reduced customer spending and overstated its resilience in tough industry conditions [3]. - The updated milestone criteria negatively impacted the company's Regenerative Medicine Program revenue, resulting in misleading statements about its business outlook [3]. Group 3: Tempus AI, Inc. (NASDAQ: TEM) - Class period is from August 6, 2024, to May 27, 2025, with a lead plaintiff deadline of August 12, 2025 [4]. - Allegations include inflation of contract values and risks associated with the joint venture with SoftBank, which appeared to involve "round-tripping" capital [4]. - Concerns were raised about the business model of Tempus-acquired Ambry, which was based on aggressive billing practices, and reduced financial commitments from AstraZeneca [4]. Group 4: Reddit, Inc. (NYSE: RDDT) - Class period is from October 29, 2024, to May 20, 2025, with a lead plaintiff deadline of August 18, 2025 [5]. - Allegations indicate that changes in Google Search algorithms led to decreased traffic to Reddit, which was not disclosed to investors [5]. - The company misrepresented its user rates and advertising revenue outlook, failing to acknowledge the impact of zero-click searches on its traffic [5].

SAN DIEGO, July 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the "Class Period"), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit.  Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with vi ...

Core Viewpoint - The article discusses a class action lawsuit against Tempus AI, Inc. due to allegations of misleading statements and inflated financial metrics during a specified class period, leading to significant stock price decline [1][2][4]. Summary by Relevant Sections Class Action Details - Investors who purchased Tempus common stock between August 6, 2024, and May 27, 2025, are reminded of the August 12, 2025, deadline to file a lead plaintiff motion [1][5]. - The lawsuit claims that the defendants made materially false and misleading statements about the company's business and operations [4]. Allegations Against Tempus - A report by Spruce Point Capital on May 28, 2025, alleged that Tempus overstated its AI capabilities and revealed weaknesses in its financial guidance [2]. - Following this report, Tempus' stock price dropped by $12.67, or 19.2%, closing at $53.20 per share [3]. Specific Misconduct Allegations - The complaint outlines several key issues: 1. Inflated value of contract agreements, including non-binding opt-ins and self-funded contracts [4]. 2. Risk to the credibility of a joint venture with SoftBank, suggesting potential "round-tripping" of capital [4]. 3. Ambry's business model involved aggressive billing practices that could face scrutiny [4]. 4. AstraZeneca's reduced financial commitments through a questionable payment structure [4]. 5. Overall, these issues indicated weaknesses in Tempus' core operations and revenue prospects [4].

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI’s top ...

Core Insights - Tempus AI (TEM) is advancing precision medicine through a strong pipeline of R&D initiatives, including the introduction of xM, a liquid biopsy assay for advanced solid tumors, and the launch of the Fuses program to enhance AI-enabled diagnostics [1][2][3] Product Development - The company launched olivia, an AI-enabled personal health concierge app, and an FDA-approved NGS-based in vitro diagnostic device, xT CDx, for solid tumor profiling [2] - Tempus AI is developing its first whole-genome sequencing test, xH, aimed at supporting personalized therapy in hematological oncology [3] Competitive Landscape - Peers like Veracyte (VCYT) and Myriad Genetics (MYGN) are also innovating in precision diagnostics, with Veracyte launching the Decipher Prostate test and Myriad introducing the Prequel Prenatal Screen and Foresight Carrier Screening test [4][5] Financial Performance - Over the past year, Tempus AI shares have increased by 83.6%, outperforming the industry growth of 38% and the S&P 500's 12.3% [6] - The company's current forward Price-to-Sales (P/S) ratio is 7.50X, higher than the industry average of 5.88X [8] Earnings Estimates - Earnings estimates for Tempus AI show a mixed outlook for 2025 and 2026, with current estimates remaining stable over the past month [10][11]